Iambic Therapeutics has raised $150 million in an initial public offering, selling about 9.4 million shares at $16 each, the midpoint of its marketed range. The San Diego company begins trading on the Nasdaq on October 15 under the symbol IAM, with the offering expected to close on October 16. At pricing, the fully diluted market value is about $809 million. Investors including existing shareholder ARK Investment Management and new investor Duquesne Family Office had indicated interest in about $60 million of the deal, roughly 40 percent of the offering. J.P. Morgan, Jefferies, BofA Securities and Citi ran the books.
Iambic is a clinical stage company built around a closed loop discovery system: proprietary AI models propose compounds, automated laboratories synthesize and test hundreds of them per program each week, and the results retrain the models. Private investors had put $462 million into the company since its founding in 2019, and it has earned collaboration revenue from partners including AbbVie, Takeda and Bayer, booking $18 million of revenue in the twelve months to June 30, 2026.
The pipeline the IPO funds is early. The lead candidate, IAM1363, is a selective, brain penetrant HER2 inhibitor in a Phase 1/1b trial in HER2 altered solid tumors, which the company says could enter a registrational trial as early as 2027. Two preclinical programs, against KIF18A and CDK2/4, are slated for investigational new drug filings in the fourth quarter.
The offering is a clean read on public market appetite for the AI discovery thesis itself. Earlier AI native drug companies that listed on platform promises have mostly traded poorly, because the value sits in clinical proof the platforms have not yet produced. Iambic priced at the midpoint rather than above range, which suggests demand was real but disciplined. Its first trading days, and the IAM1363 data cadence, will decide whether it is valued as a drug company with a useful tool or as a technology story priced ahead of its evidence.